CORAL GABLES, Fla., Sept. 2 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. has received approval from The NASDAQ Stock Market to transfer the listing of its common stock from The NASDAQ Global Market(R) to The NASDAQ Capital Market(R). The transfer will be effective at the opening of the market on September 3, 2009. Catalyst will continue to trade under the symbol “CPRX” with no impact on the ability of investors to trade the stock.
Catalyst Pharmaceutical Partners, Inc. is a biopharmaceutical company focused on the development and commercialization of prescription drugs for the treatment of addiction and obsessive-compulsive disorders. For more information about the Company, go to www.catalystpharma.com.
Catalyst Pharmaceutical Partners, Inc.